Researchers from Switzerland, the United Kingdom and the U.S. have been studying the therapy for many years. In fact, a study published in January found that the psychoactive compound helped revive emotional responsiveness in patients with treatment-resistant depression. Another showed that patients' mental benefits after two psilocybin treatments lasted for weeks.
COMPASS Pathways will begin running the first large-scale psilocybin clinical trial for treatment-resistant depression in Europe and North America within the next two years. The company’s version of psilocybin comes in powder form, synthesized in the laboratory.
"This is great news for patients,” COMPASS executive chairman George Goldsmith said in a statement. “We are excited to be taking this work forward with our clinical trial on psilocybin therapy for treatment-resistant depression. The FDA will be working closely with us to expedite the development process and increase the chances of getting this treatment to people suffering with depression as quickly as possible.”
» RELATED: CDC: Suicide rate up 16 percent in Georgia
Approximately 350 million people around the world suffer from depression, according to the World Health Organization. And in the U.S. alone, nearly 7 percent of American adults had at least one major depressive episode in 2015.
While treatments such as antidepressants and psychotherapy exist, those with severe, treatment-resistant depression often involving suicidal thoughts have trouble finding help. Approximately 100 million around the globe are affected by such treatment-resistant depression.